Hims & Hers Health, Inc. (HIMS)
Hims & Hers Shares Double on Report of Wegovy Tie-Up
Stock skyrocketed premarket following a media report that the maker of Wegovy plans to sell the weight-loss drug on the platform.
Why did HIMS stock rally 40% within hours?
Hims & Hers (NYSE: HIMS) Health stock experienced a dramatic surge in after-hours trading on Friday, transforming what had been a subdued regular session into one of the most explosive moves of the day.
Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports
Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a legal battle last month, Bloomberg News reported on Friday.
Hims and Hers Expands Its Technology Driven Consumer Health Platform
HIMS expands its tech-driven care platform with data-led Labs testing, new menopause and testosterone services and global expansion into Canada.
Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
HIMS Core Business Faces Challenges in Guidance, GLP-1 Prices & NVO
Forward-looking guidance initially plagued Hims & Hers (HIMS) shares, says Christine Short, though she believes leadership did a good job at "refocusing" goals. She points to the company's businesses beyond GLP-1s showing signs of promise.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?
Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Let's dive in.
Hims & Hers Health: Don't Get Lost In The Weeds
Hims & Hers Health, Inc. remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on track. HIMS projects 2026 revenues of $2.7–$2.9 billion, above consensus, and expects strong subscriber growth in weight loss offerings despite temporary GLP-1 headwinds. The Eucalyptus acquisition is set to add at least $200 million to 2026 revenues, positioning HIMS for a $3.25–$4 billion annualized run rate entering 2027.
Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading
Hims & Hers Health, Inc. faces severe volatility, regulatory scrutiny, and legal risks, especially in its weight-loss drug segment, yet I maintain a cautious BUY rating. Q4 results showed revenue of $617.8M (+28% YoY) and adjusted EBITDA of $66.3M, but subscriber growth and Q1 guidance disappointed due to GLP-1 headwinds. International expansion and labs initiatives are key growth drivers, with management targeting $1B+ annual international revenue and $1.3B adjusted EBITDA by 2030.
Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
HIMS reports an earnings beat and strong revenue growth in fourth-quarter 2025, but margin pressure and a softer outlook clouded the quarterly performance.
Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard
Shares of Hims & Hers Health ( NYSE:HIMS ) are trading lower this morning after yesterday's earnings, and the reason is straightforward: guidance.
